Australian biotech market today 08.04.09
Wednesday, 08 April, 2009
The pharma and biotech index is down one per cent at 3pm today, in line with the rest of the All Ordinaries.
The Big Three – Cochlear (ASX:COH), CSL (ASX:CSL) and ResMed (ASX:RMD) – have followed the rest of the index and are down on today’s trading.
Pharmaxis (ASX:PXS), which yesterday appointed US-based life science investment manager Richard van den Broek to its board, is up 8c to almost $2.
Novogen (ASX:NRT) is also up again today on very small volumes. The company today announced good results from a Phase II trial being carried out by one of its US subsidiaries, Glycotex, in wound healing. While this trial is in a cosmetic application, the company is also investigating its compound GLYC-101 in burns, surgical wounds and venous and diabetic ulcers.
Progen (ASX:PGL) is up again despite its recent dramas, settling at just over 90c today.
API manufacturer IDT Australia (ASX:IDT) is down 6c to $1.52, while Circadian (ASX:CIR) is up 3c and Clinuvel (ASX:CLV) is up 1c.
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...